Hutchmed China hails trial on sovleplenib meeting primary endpoint
(Alliance News) - Hutchmed (China) Ltd on Monday said a phase 3 trial evaluating the investigational use of sovleplenib met its primary endpoint.
Read more(Alliance News) - Hutchmed (China) Ltd on Monday said a phase 3 trial evaluating the investigational use of sovleplenib met its primary endpoint.
Read more(Sharecast News) - Hutchmed China reported a breakthrough from its recent phase three trial in sovleplenib on Monday, reporting that it met its primary endpoint and all secondary endpoints for treating adult patients with primary immune thrombocytopenia - a platelet disorder - (ITP) in China.
Read more(Alliance News) - Hutchmed (China) Ltd on Monday reported sharp first-half revenue growth, as a strategy change to boost its fortunes outside of China saw early fruit.
Read moreTuesday 25 July | |
City of London Investment Group PLC | Trading Statement |
Compass Group PLC | Trading Statement |
Croda International PLC | Half Year Results |
Games Workshop Group PLC | Full Year Results |
Greencore Group PLC | Trading Statement |
Hummingbird Resources PLC | Trading Statement |
MITIE Group PLC | Trading Statement |
Paragon Banking Group PLC | Trading Statement |
Reach PLC | Half Year Results |
Smart Metering Systems PLC | Trading Statement |
Tristel PLC | Trading Statement |
Tyman PLC | Half Year Results |
Unilever PLC | Half Year Results |
Unite Group PLC | Half Year Results |
Wednesday 26 July | |
Aptitude Software Group PLC | Half Year Results |
Breedon Group PLC | Half Year Results |
Conduit Holdings Ltd | Half Year Results |
Ecora Resources PLC | Trading Statement |
Fresnillo PLC | Trading Statement |
FRP Advisory Group PLC | Full Year Results |
Gresham Technologies PLC | Half Year Results |
Lloyds Banking Group PLC | Half Year Results |
Marston's PLC | Trading Statement |
Nichols PLC | Half Year Results |
Primary Health Properties PLC | Half Year Results |
Rathbones Group PLC | Half Year Results |
Revolution Bars Group PLC | Trading Statement |
Rio Tinto PLC | Half Year Results |
Science Group PLC | Half Year Results |
Van Elle Holdings PLC | Full Year Results |
Thursday 27 July | |
Allianz Technology Trust PLC | Half Year Results |
Antofagasta PLC | Half Year Results |
Capital & Regional PLC | Half Year Results |
Card Factory PLC | Trading Statement |
Checkit PLC | Trading Statement |
Drax Group PLC | Half Year Results |
Deliveroo PLC | Half Year Results |
Derwent London PLC | Half Year Results |
Entain PLC | Half Year Results |
Greencoat UK Wind PLC | Half Year Results |
Global Connectivity PLC | Half Year Results |
Hostelworld Group PLC | Half Year Results |
HydrogenOne Capital Growth PLC | Trading Statement |
Lancashire Holdings Ltd | Half Year Results |
Mitchells & Butlers PLC | Trading Statement |
OSB Group PLC | Half Year Results |
Persimmon PLC | Half Year Results |
Petrofac Ltd | Half Year Results |
Redcentric PLC | Full Year Results |
S&U PLC | Trading Statement |
Savills PLC | Half Year Results |
Secure Trust Bank PLC | Half Year Results |
Spirax-Sarco Engineering PLC | Half Year Results |
Videndum PLC | Half Year Results |
Wheaton Precious Metals Corp | Half Year Results |
Friday 28 July | |
AIB Group PLC | Half Year Results |
GCP Infrastructure Investments Ltd | Trading Statement |
International Consolidated Airlines Group SA | Half Year Results |
Intertek Group PLC | Half Year Results |
Jardine Matheson Holdings Ltd | Half Year Results |
NatWest Group PLC | Half Year Results |
PayPoint PLC | Full Year Results |
PayPoint PLC | Trading Statement |
Standard Chartered PLC | Half Year Results |
YouGov PLC | Trading Statement |
Monday 31 July | |
Hutchmed (China) Ltd | Half Year Results |
Pearson PLC | Half Year Results |
Pod Point Group Holdings PLC | Half Year Results |
Quartix Technologies PLC | Half Year Results |
Spectris PLC | Half Year Results |
Copyright 2023 Alliance News Ltd. All Rights Reserved. |
Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Granted breakthrough therapy designation, by the Center for Drug Evaluation of China's National Medical Products Administration, for oral inhibitor fruquintinib combined with PD-1 antibody sintilimab. BTD is for treatment of patients with previously treated advanced endometrial cancer.
Read more(Sharecast News) - Biopharmaceutical company Hutchmed China announced the launch of a phase one study in China for HMPL-415 on Monday - an investigational selective allosteric inhibitor that targeted Src homology-2 domain-containing protein tyrosine phosphatase-2 (SHP2).
Read moreHutchmed (China) Ltd - Hong Kong-based cancer and immunological diseases' treatment developer - Starts phase one study in China of its SHP2 inhibitor HMPL-415 for the treatment of advanced malignant solid tumours. First patient received their first dose on Thursday last week. Hutchmed expects up to 80 patients to take part in the study. SHP2 is a non-receptor protein tyrosine phosphatase which controls cell growth and cell migration.
Read more(Alliance News) - Hutchmed (China) Ltd on Friday said phase three results for its Fresco-2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer, conducted alongside Takeda Pharmaceutical Co Ltd, were published in peer-reviewed journal, The Lancet.
Read more(Sharecast News) - Hutchmed China, alongside its partner Takeda, announced the publication of the phase three 'FRESCO-2' study results evaluating the use of fruquintinib in patients with previously-treated metastatic colorectal cancer (CRC) on Friday, in the Lancet medical journal.
Read moreHutchmed (China) Ltd - Hong Kong-based cancer and immunological diseases treatment developer - Says marketing authorisation application for fruquintinib, made alongside Tokyo-based Takeda Pharmaceutical Co Ltd, has been validated and caccepted by the European Medicines Agency. Fruquintinib is an inhibitor of vascular endothelial growth factor receptors used to treat cancers.
Read more(Sharecast News) - Hutchmed China, in collaboration with Takeda, announced on Friday that the US Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) of fruquintinib.
Read more(Alliance News) - Hutchmed China Ltd on Friday celebrated a priority review granted by the US FDA for its cancer drug fruquintinib, and promised to present new data for this and two other therapies at the American Society of Clinical Oncology next month.
Read moreMonday 8 May | |
no events scheduled | |
Tuesday 9 May | |
Caledonia Mining Corp PLC | AGM |
Direct Line Insurance Group PLC | AGM |
Foxtons Group PLC | AGM |
Hostelworld Group PLC | AGM |
IWG PLC | AGM |
Just Group PLC | AGM |
Midwich Group PLC | AGM |
Osirium Technologies PLC | AGM |
Windward Ltd | AGM |
Wednesday 10 May | |
abrdn PLC | AGM |
Antofagasta PLC | AGM |
Cenkos Securities PLC | AGM |
Ecora Resources PLC | AGM |
H&T Group PLC | AGM |
Harbour Energy PLC | AGM |
Jupiter Fund Management PLC | AGM |
Literacy Capital PLC | AGM |
Luceco PLC | AGM |
Marshalls PLC | AGM |
National Express Group PLC | AGM |
Renewables Infrastructure Group Ltd | AGM |
Rentokil Initial PLC | AGM |
Seplat Energy PLC | AGM |
Spirax-Sarco Engineering PLC | AGM |
TClarke PLC | AGM |
Thursday 11 May | |
88 Energy Ltd | AGM |
Cairn Homes PLC | AGM |
Capita PLC | AGM |
Clarkson PLC | AGM |
Costain Group PLC | AGM |
Eleco PLC | AGM |
Eurocell PLC | AGM |
FBD Holdings PLC | AGM |
Genedrive PLC | GM re Equity Prepayment Facility |
Genel Energy PLC | AGM |
Gresham House PLC | AGM |
Gym Group PLC | AGM |
Hiscox Ltd | AGM |
Irish Continental Group PLC | AGM |
John Wood Group PLC | AGM |
MyHealthChecked PLC | AGM |
OSB Group PLC | AGM |
Poolbeg Pharma PLC | AGM |
Rolls-Royce Holdings PLC | AGM |
Serinus Energy PLC | AGM |
Uniphar PLC | AGM |
Videndum PLC | AGM |
WAG Payment Solutions PLC | AGM |
Friday 12 May | |
Balfour Beatty PLC | AGM |
Derwent London PLC | AGM |
Goodbody Health Ltd | AGM |
GreenRoc Mining PLC | AGM |
Hutchmed (China) Ltd | AGM |
Itim Group PLC | AGM |
Itsarm PLC | GM re delisting from AIM |
Wheaton Precious Metals Corp | AGM |
Copyright 2023 Alliance News Ltd. All Rights Reserved. |
(Sharecast News) - Hutchmed China announced on Tuesday that its new drug application (NDA) for fruquintinib, in combination with paclitaxel has been accepted for review by the National Medical Products Administration (NMPA) in China.
Read more(Alliance News) - Hutchmed (China) Ltd on Tuesday said the China National Medical Products Administration accepted its new drug application for fruquintinib in combination with paclitaxel.
Read more